These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22257039)

  • 1. Therapeutic effect of α-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio.
    Liao CH; Lin VC; Chung SD; Kuo HC
    Int J Clin Pract; 2012 Feb; 66(2):139-45. PubMed ID: 22257039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.
    Liao CH; Kuo YC; Kuo HC
    Urology; 2013 May; 81(5):1030-3. PubMed ID: 23506731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
    Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
    Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to choose first-line treatment for men with predominant storage lower urinary tract symptoms: a prospective randomised comparative study.
    Liao CH; Kuo HC
    Int J Clin Pract; 2015 Jan; 69(1):124-30. PubMed ID: 25495719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
    Chung DE; Te AE; Staskin DR; Kaplan SA
    Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of International Prostate Symptom Score voiding-to-storage subscore ratio in male lower urinary tract symptoms.
    Liao CH; Chung SD; Kuo HC
    Int J Clin Pract; 2011 May; 65(5):552-8. PubMed ID: 21489080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio.
    Lee CL; Kuo HC
    Urology; 2018 Oct; 120():30-35. PubMed ID: 29990572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS; Lee SH; Park KK; Yoo SJ; Chung BH
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
    Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients].
    Sun YM; Gu WD; Lü JW; Leng J; Bo JJ; Liu DM
    Zhonghua Nan Ke Xue; 2010 Sep; 16(9):790-3. PubMed ID: 21171261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.